Anderson Karen M. 的 Form 4/A 修正申報
修正Centessa Pharmaceuticals plc（CNTA），2026/3/16 申報
- 申報編號
- 0001470831-26-000279
- 申報時間
- 2026/3/16
- 交易日
- 2026/3/13
- 申報延遲
- 3 天
- 10b5-1 計畫
- 有勾選
- 原始申報日
- 2026/3/13
這份申報列了 4 筆非衍生性交易、2 筆衍生性交易。公開市場賣出合計 $315.1 萬。交易後 3 天申報。
這份修正申報取代了 0001470831-26-000268（2026/3/13 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Anderson Karen M.CIK 0001762176 | 高階主管（人資長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/3/13 | Ordinary Shares | M行使選擇權處分 | −94,224 | $0.00 | $0 | 149,811 | 直接 | |
| 2026/3/13 | Ordinary Shares | M行使選擇權處分 | −15,174 | $0.00 | $0 | 28,336 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.75 to $26.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.805 to $27.455, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
表 I 有 1 筆交易的價格引用這則附註。
- F5
25% of the shares subject to such option shall vest and become exercisable on December 1, 2023 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
- F6
1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.
備註
This Form 4/A amends and restates the Form 4 filed on March 13, 2026 to correct the reporting of stock option exercises. The exercises were previously reported as originating from a single option grant but were exercised from two separate option grants with different exercise prices. This amendment reports the exercises from each grant at the applicable exercise prices. Except for the corrected reporting of the option exercises, the transactions and amounts previously reported remain unchanged.